Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Cell Specific Gene Expression

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy and Safety of Bariatric Surgery in Acquired Hypothalamic Obesity: A Systematic Review and Individual Patient Data Meta-Analysis.

Obesity reviews : an official journal of the International Association for the Study of Obesity·2026

Same author

Defining Acquired Hypothalamic Obesity: An Expert Call for Unified Diagnosis and Therapeutic Action.

Diabetes, obesity & metabolism·2026

Same author

SEMASEARCH Study Design: Real-World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials.

Diabetes, obesity & metabolism·2026

Same author

Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disorders.

The Journal of clinical endocrinology and metabolism·2026

Same author

Characterization of jejunal enteroids in human obesity; a model for studying GLP-1 cells.

International journal of obesity (2005)·2026

Same author

Prominent mediatory role of gut microbiome in the effect of lifestyle on host metabolic phenotypes.

Gut microbes·2025

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation

Published on: August 4, 2023

Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.

Jean-Marc Guettier¹, Jean Y Park¹, Elaine K Cochran¹

¹Clinical Endocrinology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.

Clinical Endocrinology

|December 14, 2007

Summary

Recombinant human leptin (r-metHuLeptin) therapy significantly improved metabolic abnormalities in a patient with partial lipodystrophy (PL) caused by a PPARG mutation. This suggests leptin therapy

More Related Videos

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Related Experiment Videos

Last Updated: Jul 9, 2026

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation

Isolation of Targeted Hypothalamic Neurons for Studies of Hormonal, Metabolic, and Electrical Regulation

Published on: August 4, 2023

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

White and Brown Adipose Grafts: An Approach to Correct Reproductive, Metabolic, and Renal Deficits in Black and Tan Brachyury (BTBR) Obese Mice

Published on: September 9, 2025

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Area of Science:

Endocrinology
Metabolic Disorders
Genetics

Background:

Partial lipodystrophy (PL) is characterized by fat loss and metabolic complications like insulin resistance, diabetes, and hyperlipidemia.
Recombinant human leptin (r-metHuLeptin) is effective for generalized lipodystrophy and PL linked to LMNA mutations or HAART.
The efficacy of r-metHuLeptin in PL associated with PPARG mutations was previously unestablished.

Observation:

A 36-year-old female with PL due to a heterozygous PPARG mutation presented with uncontrolled diabetes and severe hypertriglyceridemia.
The patient underwent an 18-month treatment protocol with escalating doses of r-metHuLeptin.
Metabolic parameters, body composition, and energy expenditure were monitored throughout the study.

Findings:

Eighteen months of r-metHuLeptin therapy led to normalized fasting blood glucose and improved HbA1c levels.
Significant reduction in severe hypertriglyceridemia was observed, with levels decreasing from 21.15 mmol/l to 5.96 mmol/l.
The patient demonstrated improved glucose tolerance during an oral glucose tolerance test.

Implications:

r-metHuLeptin effectively treats metabolic complications in partial lipodystrophy patients with PPARG mutations.
Leptin therapy's beneficial effects appear independent of the specific genetic cause of lipodystrophy.
These findings expand the therapeutic potential of r-metHuLeptin for diverse forms of lipodystrophy.